- Home
- CPRX
as 01-17-2025 4:00pm EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.5B | IPO Year: | 2006 |
| Target Price: | $32.86 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.18 | EPS Growth: | 114.68 |
| 52 Week Low/High: | $13.12 - $24.27 | Next Earning Date: | 02-26-2025 |
| Revenue: | $460,482,000 | Revenue Growth: | 32.17% |
| Revenue Growth (this year): | 23.98% | Revenue Growth (next year): | 18.27% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Miller Steve | CPRX | Chief Op. & Scientific Officer | Dec 9 '24 | Sell | $21.93 | 50,000 | $1,096,350.00 | 686,996 | |
| Harper Molly | CPRX | Director | Nov 27 '24 | Sell | $22.00 | 17,500 | $385,000.00 | 0 | |
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Nov 27 '24 | Sell | $22.71 | 12,000 | $272,654.28 | 51,391 | |
| Elsbernd Brian | CPRX | Chief Compliance/Legal Officer | Nov 26 '24 | Sell | $21.61 | 13,256 | $286,703.61 | 171,177 | |
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Nov 20 '24 | Sell | $21.20 | 38,000 | $805,562.00 | 51,391 | |
| MCENANY PATRICK J | CPRX | Director | Nov 19 '24 | Sell | $21.24 | 170,845 | $3,627,258.86 | 4,478,169 | |
| MCENANY PATRICK J | CPRX | Director | Nov 13 '24 | Sell | $22.37 | 137,155 | $3,096,800.56 | 4,478,169 | |
| MCENANY PATRICK J | CPRX | Director | Nov 11 '24 | Sell | $23.39 | 492,000 | $11,510,102.00 | 4,478,169 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
3 days ago
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Argus Research
4 days ago
CPRX: Raising target price to $23.00
Investor's Business Daily
4 days ago
BridgeBio Pharma Stock Earns 87 RS Rating
Zacks
10 days ago
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Investor's Business Daily
10 days ago
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
GlobeNewswire
10 days ago
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Zacks
12 days ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Zacks
16 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.